A Phase 3 interventional study of Bendamustine and Venetoclax in Chronic Lymphocytic Leukemia, sponsored by Hoffmann-La Roche. Completed at 111 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-17.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment, is one of 6 that started in 2014, is one of 15 in phase 3, and was the 6th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Kerry Rogers · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
City of Hope Medical Center · Sites in United States
Ages 18+
Zulfa Omer · Sites in United States
Ages 18+
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 44 · Phase 3 15 · Phase 4 1
First in 2011; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 389 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 72 across the 69 interventional studies. Of the 24 that completed or were terminated, 12 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 69 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche: 1 open now, 2 under way, none of them phase 3. Of 46 finished, 28 (61%) have results posted.
Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2014, is one of 10 in phase 3, and was the 33rd registered.
Hoffmann-La Roche’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2003.
13 of the studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04895436AbbVieStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) | 2026-11 |
| NCT03467867Georgetown UniversityA Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | 2026-12 |
| NCT04588922Sellas Life Sciences GroupStudy of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Hoffmann-La Roche’s 48 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the benefit of venetoclax in combination with rituximab compared with bendamustine in combination with rituximab in participants with relapsed or refractory CLL. Participants will be randomly assigned in 1:1 ratio to receive either venetoclax + rituximab (Arm A) or bendamustine + rituximab (Arm B).
Inclusion Criteria:
Inclusion Criteria R/C Substudy:
Exclusion Criteria:
Exclusion Criteria R/C Substudy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive bendamustine 70 milligrams per meter square (mg/m\^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
Drug: Bendamustine · Drug: Rituximab
Participants will be initially placed on a venetoclax 5 weeks ramp-up period, and will receive an initial dose of 20 milligrams (mg) via tablet orally once daily (QD). Then the dose will be incremented weekly up to a maximum dose of 400 mg. Participants will then continue receiving venetoclax 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards, as directed by the investigator, in combination with rituximab 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m\^2 on Day 1 of Cycles 2-6.
Drug: Venetoclax · Drug: Rituximab
Participants entering the Crossover Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Crossover Day 1 of the Substudy.
Drug: Venetoclax · Drug: Rituximab
Participants entering the Re-Treatment Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Re-Treatment Day 1 of the Substudy.
Drug: Venetoclax · Drug: Rituximab
Bendamustine will be administered at a dose of 70 mg/m\^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first. R/C Substudy: venetoclax will be administered for 5-week dose ramp-up period to reach the target dose of 400 mg QD. Venetoclax will continue to be administered during the rituximab cycles until disease progression or for a maximum of 2 years from Cycle 1R/C Day 1 of the R/C Substudy.
Also known as: GDC-0199, ABT-199
Rituximab will be administered at a dose of 375 mg/m\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\^2 on Day 1 of Cycles 2-6. R/C Substudy: Following the venetoclax ramp-up period, rituximab will be administered for 6 cycles consisting of a single infusion on the first day of each 28-day cycle.
Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death
Assessment of response was performed by the investigator according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (greater than \[\>\] 1.5 centimeters \[cm\]); unequivocal progression of non-target lesion; an increase of greater than or equal to (\>/=) 50 percent (%) compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000 per microliter (mcL), or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 grams per deciliter (g/dL) or to less than \[\<\] 10 g/dL. Percentages are rounded off.
Time frame: Baseline up to PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)
Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines
PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the investigator using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% confidence interval (CI) was computed using method of Brookmeyer and Crowley.
Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)
Percentage of Participants With PD or Death as Assessed by the Independent Review Committee (IRC) Using Standard iwCLL Guidelines
Assessment of response was performed by the IRC according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. No new IRC data was generated post the primary analysis.
Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 3 years)
PFS as Assessed by the IRC Using Standard iwCLL Guidelines
PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the IRC using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. No new IRC data was generated post the primary analysis.
Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 3 years)
Percentage of Participants With PD or Death as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by Fluorescence In-situ Hybridization (FISH) Test
Assessment of response was performed by the investigator according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. Percentages are rounded off.
Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)
PFS as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test
PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the investigator using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.
Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 8 years 5 months)
Percentage of Participants With PD or Death as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test
Assessment of response was performed by the IRC according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. No new IRC data was generated post the primary analysis.
Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 3 years)
PFS as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test
PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the IRC using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. No new IRC data was generated post the primary analysis.
Time frame: Baseline up to PD or death, whichever occurred first (up to approximately 3 years)
Percentage of Participants With Best Overall Response of Complete Response (CR), CR With Incomplete Bone Marrow Recovery (CRi), Nodular Partial Response (nPR), or Partial Response (PR) as Assessed by the Investigator Using iwCLL Guidelines
Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in two of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.Percentages are rounded off.
Time frame: Baseline up to approximately 8 years 5 months
Percentage of Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the IRC Using iwCLL Guidelines
Response was assessed by IRC according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in 2 of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.No new IRC data was generated post primary analysis.
Time frame: Baseline up to last FUV (up to approximately 3 years)
Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the Investigator Using iwCLL Guidelines
Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in 2 of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method. Percentages are rounded off.
Time frame: End of combination treatment response (EoCTR) visit (8 to 12 weeks after Cycle [C] 6 Day [1]); Cycle length = 28 days
Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the IRC Using iwCLL Guidelines
Response was assessed by the IRC according to the iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in two of the following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and one of the following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. The 95% CI was computed using Pearson-Clopper method.
Time frame: EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days
Percentage of Participants Who Died
Percentage of participants who died from any cause, during the study, was reported. Percentage is rounded off.
Time frame: Baseline up to approximately 8 years 5 months
Overall Survival (OS)
OS was defined as the time from the date of randomization to the date of death from any cause. Participants alive at the time of the analysis were censored at the date when they were last known to be alive as documented by the investigator. The median OS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.
Time frame: Baseline up to approximately 8 years 5 months
Percentage of Participants With PD/Relapse, Start of a New Anti-Chronic Lymphocytic Leukemia (CLL) Therapy, or Death as Assessed by the Investigator Using iwCLL Guidelines
Percentage of participants with PD/relapse, death from any cause, or start of a new non-protocol-specified anti-CLL therapy as assessed by the investigator, during the study, was reported. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. Percentages are rounded off.
Time frame: Baseline up to PD/relapse, start of a new anti-CLL therapy, or death from any cause, whichever occurred first (approximately 8 years 5 months)
Event-Free Survival (EFS) as Assessed by the Investigator Using iwCLL Guidelines
EFS was defined as the time from date of randomization until the date of PD/relapse, start of a new non-protocol-specified anti-CLL therapy, or death from any cause, whichever occurred first, as assessed by the investigator. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants without any of the specified event at the time of analysis were censored at the date of last adequate response assessment. In case of no post-baseline response assessment, participants were censored at the randomization date. The median EFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.
Time frame: Baseline up to PD/relapse, start of a new anti-CLL therapy, or death from any cause, whichever occurred first (approximately 8 years 5 months)
Percentage of Participants With PD or Death Among Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the Investigator Using iwCLL Guidelines
Percentage of participants with PD as assessed by the investigator according to the iwCLL guidelines or death from any cause during the study was reported. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint. Percentage is rounded off.
Time frame: From time of achieving best overall response until PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)
Duration of Responses (DOR) as Assessed by the Investigator Using iwCLL Guidelines
DOR was defined as the time from first occurrence of a documented response of CR, CRi, nPR, or PR until PD/relapse, as assessed by the investigator according to the iwCLL guidelines, or death from any cause. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants without PD or death after response were censored at the last date of adequate response assessment. The median DOR was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint.
Time frame: From time of achieving best overall response until PD or death from any cause, whichever occurred first (up to approximately 8 years 5 months)
Percentage of Participants With Start of New Anti-CLL Treatment or Death as Assessed by the Investigator
Percentage of participants with start of new non-protocol-specified anti-CLL therapy, as assessed by the investigator, or death from any cause, during the study, was reported. Percentage is rounded off.
Time frame: Baseline up to start of new ani-CLL therapy or death, whichever occurred first (up to approximately 8 years 5 months)
Time to New Anti-CLL Treatment (TTNT) as Assessed by the Investigator
TTNT was defined as the time from randomization until start of new non-protocol-specified anti-CLL treatment or death from any cause. Participants without the event at the time of analysis were censored at the last visit date for this outcome measure analysis. The median TTNT was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.
Time frame: Baseline up to start of new ani-CLL therapy or death, whichever occurred first (up to approximately 8 years 5 months)
Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood
MRD-negativity was defined as the presence of \<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed by the allele specific oligonucleotide polymerase chain reaction (ASO-PCR) and/or flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentage is rounded off.
Time frame: EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days
Percentage of Participants With MRD Negativity in Bone Marrow
MRD-negativity was defined as the presence of \<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentages are rounded off.
Time frame: EoCTR visit (8 to 12 weeks after C6D1); Cycle length = 28 days
Plasma Venetoclax Concentrations
Time frame: Pre-dose (0 hour, anytime before venetoclax administration) and 4 hours post-dose on D1 of Cycles 1 and 4; Cycle length = 28 days
Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Core Symptom Severity, Module Symptom Severity, and Interference Scores
MDASI is a 25-item validated questionnaire consisting of 2 parts. Part 1: 19-items divided into 2 scales, Core Symptom Severity (average of Questions 1 to 13; total 13 items: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness) and Module Symptom Severity (average of Questions 14 to 19; total 6 items: night sweats, fevers and chills, lymph node swelling, diarrhea, bruising easy or bleeding, and constipation). Part 2: 6-items to assess Interference (symptom distress) (average of Questions 20 to 25; total 6 items: general activity, walking, work, mood, relations with other people, and enjoyment of life). Each item was rated from 0 to 10, with lower scores indicating better outcome. Total score for Core Symptom Severity, Module Symptom Severity, and Interference are reported which range from 0 to 10, with lower scores indicating better health-related quality of life (HRQoL).
Time frame: Baseline, Days 1, 8, and 15 of Cycles 1, 2, and 3; Cycle length = 28 days
Change From Baseline in HRQoL as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scales Score and Global Health Status/Global Quality-of-Life (QoL) Scale Score
EORTC QLQ-C30 is a validated self-report measure consisting of 30 questions incorporated into 5 functional scales (Physical, Role, Cognitive, Emotional, and Social), 3 symptom scales (fatigue, pain, nausea, and vomiting), a global health status/global QoL scale, and single items (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea). Most questions used 4-point scale (1='Not at all' to 4='Very much'), while 2 questions used 7-point scale (1='very poor' to 7='Excellent'). Scores were averaged, transformed to 0-100 scale; where higher score for functional scales=poor level of functioning; higher score for global health status/global QoL=better HRQoL.
Time frame: Baseline, D1 of Cycles 1, 2, 3, 4, 5, 6, STC/EW visit (up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days
Change From Baseline in HRQoL as Measured by Quality of Life Questionnaire Associated CLL Module (QLQ-CLL16) Multi-Item Scales Score
The EORTC QLQ-CLL16 module is designed for participants with Stage 0 to Stage 4 CLL. It is composed of 16 questions and there are four multi-item scales on Fatigue (2 items), Treatment-related side effects (TRSE, 4 items), Disease-related symptoms (DRS, 4 items), and Infection (4 items); and two single-item scales on social activities and future health worries. Multi-item scales score are reported and the total score for each multi-item scale was transformed to result in a total score range of 0 to 100, where higher score = poor HRQoL.
Time frame: Baseline, D1 of Cycles 1, 2, 3, 4, 5, 6, STC/EW visit (up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A Serious Adverse Event (SAE) is any significant hazard, contraindication, side effect that is fatal or life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above. AEs were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE, v4.0)
Time frame: From signing of informed consent form up to approximately 8 years 5 months
Number of Participants With Grade 3 or Higher Tumor Lysis Syndrome (TLS) and Infusion-related Reactions (IRRs)
An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A SAE is any significant hazard, contraindication, side effect that is fatal or life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above. TLS and IRRs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening; Grade 5 = Death. A higher grade indicates a worse outcome.
Time frame: From signing of informed consent form up to approximately 8 years 5 months
Change From Baseline in Lymphocyte Subset Counts at Specified Time Points
Time frame: Baseline, C4D14-28, Study Treatment Completion/Early Withdrawal (STC/EW, up to C6D28), EoCTR visit (8 to 12 weeks after C6D1), and at FUVs (every 12 weeks after EoCTR up to 3 years); Cycle length = 28 days
A total 389 participants took part in the study across 109 investigative sites in 20 countries i.e., Korea, Taiwan, Australia, New Zealand, Czech Republic, Hungary, Poland, Russia, Canada, United States of America, Austria, Belgium, Germany, Denmark, Spain, France, United Kingdom, Italy, Netherlands and Sweden from 17 March 2014 to 03 August 2022. The trial consisted of a main study and an optional Retreatment/Crossover (R/C) sub study.
| Milestone | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study | Bendamustine + Rituximab Crossover Substudy | Venetoclax + Rituximab Re-Treatment Substudy |
|---|---|---|---|---|
| Started | 195 | 194 | 0 | 0 |
| Safety evaluable (se) population | 188 | 194 | 0 | 0 |
| Completed | 71 | 118 | 0 | 0 |
| Not completed | 124 | 76 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Death | 83 | 52 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 5 | 0 | 0 |
| Withdrew: Physician decision | 3 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 26 | 11 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 6 | 0 | 0 |
| Withdrew: Randomized but not dosed | 8 | 0 | 0 | 0 |
| Milestone | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study | Bendamustine + Rituximab Crossover Substudy | Venetoclax + Rituximab Re-Treatment Substudy |
|---|---|---|---|---|
| Started | 0 | 0 | 9 | 25 |
| Completed | 0 | 0 | 7 | 15 |
| Not completed | 0 | 0 | 2 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 8 |
Assessment of response was performed by the investigator according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (greater than \[\>\] 1.5 centimeters \[cm\]); unequivocal progression of non-target lesion; an increase of greater than or equal to (\>/=) 50 percent (%) compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000 per microliter (mcL), or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 grams per deciliter (g/dL) or to less than \[\<\] 10 g/dL. Percentages are rounded off.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death | 88.7 | 70.1 |
PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the investigator using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% confidence interval (CI) was computed using method of Brookmeyer and Crowley.
| months | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines | 17.0 (15.5 to 21.7) | 54.7 (52.3 to 59.9) |
Assessment of response was performed by the IRC according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. No new IRC data was generated post the primary analysis.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants With PD or Death as Assessed by the Independent Review Committee (IRC) Using Standard iwCLL Guidelines | 54.4 | 18.0 |
PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the IRC using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. No new IRC data was generated post the primary analysis.
| months | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| PFS as Assessed by the IRC Using Standard iwCLL Guidelines | 18.1 (15.8 to 22.3) | NA (NA to NA) |
Assessment of response was performed by the investigator according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. Percentages are rounded off.
| percentage of participants | Bendamustine + Rituximab 17p Del. Population | Venetoclax + Rituximab 17p Del. Population |
|---|---|---|
| Percentage of Participants With PD or Death as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by Fluorescence In-situ Hybridization (FISH) Test | 80.4 | 80.4 |
PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the investigator using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.
| months | Bendamustine + Rituximab 17p Del. Population | Venetoclax + Rituximab 17p Del. Population |
|---|---|---|
| PFS as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test | 15.4 (10.0 to 21.0) | 47.9 (37.4 to 59.9) |
Assessment of response was performed by the IRC according to the iwCLL guidelines. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. No new IRC data was generated post the primary analysis.
| percentage of participants | Bendamustine + Rituximab 17p Del. Population | Venetoclax + Rituximab 17p Del. Population |
|---|---|---|
| Percentage of Participants With PD or Death as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test | 47.8 | 19.6 |
PFS was defined as the time from randomization until first occurrence of PD/relapse as assessed by the IRC using iwCLL guidelines, or death from any cause, whichever occurred first. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants who had not progressed, relapsed, or died at the time of analysis, were censored on the date of last assessment. In case of no disease assessment after baseline, PFS was censored at the time of randomization+1 day. The median PFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. No new IRC data was generated post the primary analysis.
| months | Bendamustine + Rituximab 17p Del. Population | Venetoclax + Rituximab 17p Del. Population |
|---|---|---|
| PFS as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test | 16.1 (13.6 to 22.3) | NA (27.6 to NA) |
Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in two of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.Percentages are rounded off.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| CR | 8.2 (4.76 to 12.98) | 26.3 (20.24 to 33.07) |
| CRi | 0.5 (0.01 to 2.82) | 1.5 (0.32 to 4.45) |
| nPR | 6.2 (3.22 to 10.50) | 3.6 (1.46 to 7.29) |
| PR | 52.8 (45.56 to 59.99) | 61.9 (54.62 to 68.72) |
Response was assessed by IRC according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in 2 of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.No new IRC data was generated post primary analysis.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the IRC Using iwCLL Guidelines | 67.7 (60.64 to 74.20) | 93.3 (88.81 to 96.38) |
Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in 2 of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method. Percentages are rounded off.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the Investigator Using iwCLL Guidelines | 63.1 (55.89 to 69.86) | 88.1 (82.74 to 92.33) |
Response was assessed by the IRC according to the iwCLL guidelines and was confirmed by repeat assessment \>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \>/=50% reduction in two of the following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and one of the following: neutrophils \>1500/mcL, platelets \>100000/mcL, hemoglobin \>11.0 g/dL or \>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. The 95% CI was computed using Pearson-Clopper method.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the IRC Using iwCLL Guidelines | 62.6 (55.37 to 69.37) | 87.1 (81.57 to 91.48) |
Percentage of participants who died from any cause, during the study, was reported. Percentage is rounded off.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants Who Died | 43.1 | 30.9 |
OS was defined as the time from the date of randomization to the date of death from any cause. Participants alive at the time of the analysis were censored at the date when they were last known to be alive as documented by the investigator. The median OS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.
| months | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Overall Survival (OS) | 87.8 (70.1 to NA) | NA (NA to NA) |
Percentage of participants with PD/relapse, death from any cause, or start of a new non-protocol-specified anti-CLL therapy as assessed by the investigator, during the study, was reported. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. Percentages are rounded off.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants With PD/Relapse, Start of a New Anti-Chronic Lymphocytic Leukemia (CLL) Therapy, or Death as Assessed by the Investigator Using iwCLL Guidelines | 89.2 | 71.1 |
EFS was defined as the time from date of randomization until the date of PD/relapse, start of a new non-protocol-specified anti-CLL therapy, or death from any cause, whichever occurred first, as assessed by the investigator. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants without any of the specified event at the time of analysis were censored at the date of last adequate response assessment. In case of no post-baseline response assessment, participants were censored at the randomization date. The median EFS was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.
| months | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Event-Free Survival (EFS) as Assessed by the Investigator Using iwCLL Guidelines | 16.4 (14.2 to 21.0) | 53.7 (48.5 to 59.3) |
Percentage of participants with PD as assessed by the investigator according to the iwCLL guidelines or death from any cause during the study was reported. PD was defined as occurrence of one of the following events: appearance of any new extra nodal lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; an increase of \>/=50% compared to baseline in splenomegaly, hepatomegaly, number of blood lymphocytes with lymphocyte count \>/=5000/mcL, or in longest diameter of any extra nodal lesion; transformation to a more aggressive histology; decrease of \>/=50% compared to baseline in platelet or neutrophil count; or decrease in hemoglobin level by \>2 g/dL or to \<10 g/dL. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint. Percentage is rounded off.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants With PD or Death Among Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the Investigator Using iwCLL Guidelines | 95.5 | 68.5 |
DOR was defined as the time from first occurrence of a documented response of CR, CRi, nPR, or PR until PD/relapse, as assessed by the investigator according to the iwCLL guidelines, or death from any cause. PD: occurrence of one of the following: new lesion; new palpable lymph node (\>1.5 cm); unequivocal progression of non-target lesion; increase of \>/=50% in splenomegaly, hepatomegaly, blood lymphocytes with count \>/=5000/mcL, longest diameter of any lesion; transformation to more aggressive histology; decrease of \>/=50% in platelet or neutrophil count, or hemoglobin level by \>2 g/dL or to \<10 g/dL. Participants without PD or death after response were censored at the last date of adequate response assessment. The median DOR was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley. CR, CRi, nPR, and PR have been defined in previous outcomes, and are not repeated here due to space constraint.
| months | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Duration of Responses (DOR) as Assessed by the Investigator Using iwCLL Guidelines | 19.1 (16.1 to 23.6) | 53.6 (49.1 to 57.0) |
Percentage of participants with start of new non-protocol-specified anti-CLL therapy, as assessed by the investigator, or death from any cause, during the study, was reported. Percentage is rounded off.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants With Start of New Anti-CLL Treatment or Death as Assessed by the Investigator | 81.5 | 62.4 |
TTNT was defined as the time from randomization until start of new non-protocol-specified anti-CLL treatment or death from any cause. Participants without the event at the time of analysis were censored at the last visit date for this outcome measure analysis. The median TTNT was estimated using Kaplan-Meier method and the 95% CI was computed using method of Brookmeyer and Crowley.
| months | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Time to New Anti-CLL Treatment (TTNT) as Assessed by the Investigator | 24.0 (20.7 to 29.5) | 63.0 (56.1 to 73.6) |
MRD-negativity was defined as the presence of \<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed by the allele specific oligonucleotide polymerase chain reaction (ASO-PCR) and/or flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentage is rounded off.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood | 13.3 (8.90 to 18.92) | 62.4 (55.15 to 69.21) |
MRD-negativity was defined as the presence of \<1 malignant B-cell per 10000 normal B-cells in a sample of at least 200000 B-cells, as assessed flow cytometry technique. Percentage of participants with MRD-negativity was reported. The 95% CI was computed using Pearson-Clopper method. Percentages are rounded off.
| percentage of participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Percentage of Participants With MRD Negativity in Bone Marrow | 1.0 (0.12 to 3.66) | 14.4 (9.81 to 20.18) |
| micrograms per milliliter (mcg/mL) | Venetoclax + Rituximab Main Study |
|---|---|
| C1D1, Pre-dose | 0.626 ± 0.540 |
| C1D1, 4 hours Post-Dose | 1.34 ± 0.881 |
| C4D1, Pre-dose | 0.681 ± 0.745 |
| C4D1, 4 hours Post-Dose | 1.34 ± 0.905 |
MDASI is a 25-item validated questionnaire consisting of 2 parts. Part 1: 19-items divided into 2 scales, Core Symptom Severity (average of Questions 1 to 13; total 13 items: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, and numbness) and Module Symptom Severity (average of Questions 14 to 19; total 6 items: night sweats, fevers and chills, lymph node swelling, diarrhea, bruising easy or bleeding, and constipation). Part 2: 6-items to assess Interference (symptom distress) (average of Questions 20 to 25; total 6 items: general activity, walking, work, mood, relations with other people, and enjoyment of life). Each item was rated from 0 to 10, with lower scores indicating better outcome. Total score for Core Symptom Severity, Module Symptom Severity, and Interference are reported which range from 0 to 10, with lower scores indicating better health-related quality of life (HRQoL).
| units on a scale | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Baseline; Mean core symptom severity | 1.76 ± 1.55 | 1.55 ± 1.31 |
| Change at C1D1; Mean core symptom severity | 0.00 ± 0.00 | -0.08 ± 0.98 |
| Change at C1D8; Mean core symptom severity | 0.26 ± 1.34 | -0.30 ± 0.84 |
| Change at C1D15; Mean core symptom severity | 0.00 ± 1.31 | -0.27 ± 0.93 |
| Change at C2D1; Mean core symptom severity | -0.23 ± 1.30 | -0.33 ± 0.91 |
| Change at C2D8; Mean core symptom severity | 0.17 ± 1.59 | -0.45 ± 0.91 |
| Change at C2D15; Mean core symptom severity | -0.13 ± 1.53 | -0.53 ± 0.90 |
| Change at C3D1; Mean core symptom severity | -0.26 ± 1.60 | -0.40 ± 1.13 |
| Change at C3D8; Mean core symptom severity | -0.13 ± 1.63 | -0.66 ± 1.20 |
| Change at C3D15; Mean core symptom severity | -0.42 ± 1.52 | -0.53 ± 1.05 |
| Baseline; Mean module symptom severity | 1.60 ± 1.46 | 1.57 ± 1.11 |
| Change at C1D1; Mean module symptom severity | 0.00 ± 0.00 | -0.19 ± 0.96 |
| Change at C1D8; Mean module symptom severity | -0.22 ± 1.40 | -0.53 ± 0.96 |
| Change at C1D15; Mean module symptom severity | -0.43 ± 1.51 | -0.73 ± 1.13 |
| Change at C2D1; Mean module symptom severity | -0.49 ± 1.46 | -0.65 ± 0.92 |
| Change at C2D8; Mean module symptom severity | -0.46 ± 1.63 | -0.77 ± 0.87 |
| Change at C2D15; Mean module symptom severity | -0.69 ± 1.47 | -0.94 ± 0.93 |
| Change at C3D1; Mean module symptom severity | -0.65 ± 1.48 | -0.81 ± 0.97 |
| Change at C3D8; Mean module symptom severity | -0.51 ± 1.58 | -0.83 ± 0.97 |
| Change at C3D15; Mean module symptom severity | -0.83 ± 1.51 | -0.92 ± 0.97 |
| Baseline; Mean interference | 1.81 ± 2.05 | 1.90 ± 2.25 |
| Change at C1D1; Mean interference | 0.00 ± 0.00 | -0.13 ± 1.49 |
| Change at C1D8; Mean interference | 0.45 ± 1.78 | -0.29 ± 2.14 |
| Change at C1D15; Mean interference | 0.36 ± 1.85 | 0.01 ± 2.04 |
| Change at C2D1; Mean interference | 0.01 ± 1.73 | -0.34 ± 1.78 |
| Change at C2D8; Mean interference | 0.58 ± 2.20 | -0.58 ± 1.81 |
| Change at C2D15; Mean interference | 0.06 ± 1.84 | -0.64 ± 1.59 |
| Change at C3D1; Mean interference | -0.02 ± 2.02 | -0.73 ± 2.06 |
| Change at C3D8; Mean interference | 0.15 ± 1.91 | -0.82 ± 2.09 |
| Change at C3D15; Mean interference | -0.07 ± 2.01 | -0.55 ± 2.18 |
EORTC QLQ-C30 is a validated self-report measure consisting of 30 questions incorporated into 5 functional scales (Physical, Role, Cognitive, Emotional, and Social), 3 symptom scales (fatigue, pain, nausea, and vomiting), a global health status/global QoL scale, and single items (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea). Most questions used 4-point scale (1='Not at all' to 4='Very much'), while 2 questions used 7-point scale (1='very poor' to 7='Excellent'). Scores were averaged, transformed to 0-100 scale; where higher score for functional scales=poor level of functioning; higher score for global health status/global QoL=better HRQoL.
| units on a scale | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Baseline; Physical functioning | 82.59 ± 17.46 | 83.77 ± 15.27 |
| Change at C1D1; Physical functioning | 0.0 ± 0.0 | 1.39 ± 12.90 |
| Change at C2D1; Physical functioning | 0.31 ± 15.81 | 2.99 ± 12.83 |
| Change at C3D1; Physical functioning | 0.22 ± 16.43 | 1.46 ± 14.76 |
| Change at C4D1; Physical functioning | 2.11 ± 14.95 | 5.54 ± 14.17 |
| Change at C5D1; Physical functioning | 2.44 ± 18.19 | 4.62 ± 15.27 |
| Change at C6D1; Physical functioning | 2.25 ± 16.82 | 4.51 ± 16.59 |
| Change at STC/EW; Physical functioning | 1.68 ± 18.76 | 4.53 ± 16.04 |
| Change at EoCTR; Physical functioning | 2.92 ± 18.03 | 4.34 ± 16.12 |
| Change at FUV1; Physical functioning | 2.27 ± 18.86 | 3.81 ± 16.27 |
| Change at FUV2; Physical functioning | 2.40 ± 19.21 | 2.75 ± 17.17 |
| Change at FUV3; Physical functioning | 2.54 ± 17.83 | 3.44 ± 17.31 |
| Change at FUV4; Physical functioning | 4.74 ± 20.14 | 0.85 ± 21.06 |
| Change at FUV5; Physical functioning | 1.90 ± 17.68 | -1.75 ± 19.35 |
| Change at FUV6; Physical functioning | -1.41 ± 15.34 | 1.33 ± 5.58 |
| Change at FUV7; Physical functioning | -3.08 ± 11.74 | 0.00 |
| Change at FUV8; Physical functioning | -9.33 ± 23.38 | 0.00 |
| Change at FUV9; Physical functioning | -10.00 ± 33.0 | — |
| Baseline; Role functioning | 78.25 ± 25.67 | 83.82 ± 21.00 |
| Change at C1D1; Role functioning | 0.0 ± 0.0 | -1.74 ± 23.23 |
| Change at C2D1; Role functioning | -1.26 ± 27.45 | 2.49 ± 23.07 |
| Change at C3D1; Role functioning | -0.10 ± 29.64 | 1.82 ± 26.08 |
| Change at C4D1; Role functioning | 0.87 ± 29.01 | 5.13 ± 22.03 |
| Change at C5D1; Role functioning | 0.45 ± 30.75 | 4.36 ± 23.44 |
| Change at C6D1; Role functioning | 0.70 ± 29.92 | 1.79 ± 25.71 |
| Change at STC/EW; Role functioning | -0.41 ± 32.91 | 2.60 ± 25.58 |
| Change at EoCTR; Role functioning | 3.26 ± 29.95 | 2.12 ± 26.69 |
| Change at FUV1; Role functioning | 2.93 ± 32.31 | 2.65 ± 27.47 |
| Change at FUV2; Role functioning | 3.07 ± 32.63 | -1.85 ± 31.84 |
| Change at FUV3; Role functioning | 5.26 ± 31.16 | 1.88 ± 28.17 |
| Change at FUV4; Role functioning | 5.41 ± 33.16 | -0.35 ± 30.39 |
| Change at FUV5; Role functioning | 2.34 ± 29.79 | 1.75 ± 34.20 |
| Change at FUV6; Role functioning | -4.04 ± 27.01 | -13.33 ± 32.06 |
| Change at FUV7; Role functioning | 2.56 ± 29.54 | -16.67 |
| Change at FUV8; Role functioning | 0.00 ± 23.57 | 16.67 |
| Change at FUV9; Role functioning | -16.67 ± 23.57 | — |
| Baseline; Emotional functioning | 78.98 ± 22.47 | 82.13 ± 15.80 |
| Change at C1D1; Emotional functioning | 0.0 ± 0.0 | 4.35 ± 15.17 |
| Change at C2D1; Emotional functioning | 2.24 ± 20.07 | 5.60 ± 14.68 |
| Change at C3D1; Emotional functioning | 2.99 ± 20.06 | 5.34 ± 19.09 |
| Change at C4D1; Emotional functioning | 2.61 ± 18.35 | 4.19 ± 15.45 |
| Change at C5D1; Emotional functioning | 1.14 ± 18.79 | 3.97 ± 17.37 |
| Change at C6D1; Emotional functioning | 2.06 ± 18.74 | 3.08 ± 17.96 |
| Change at STC/EW; Emotional functioning | 2.43 ± 20.61 | 5.34 ± 18.69 |
| Change at EoCTR; Emotional functioning | 2.58 ± 19.45 | 3.49 ± 17.83 |
| Change at FUV1; Emotional functioning | 3.49 ± 20.91 | 4.37 ± 18.50 |
| Change at FUV2; Emotional functioning | 4.39 ± 20.33 | 0.66 ± 21.02 |
| Change at FUV3; Emotional functioning | 0.63 ± 19.97 | 2.82 ± 17.66 |
| Change at FUV4; Emotional functioning | 4.82 ± 19.73 | 1.95 ± 18.41 |
| Change at FUV5; Emotional functioning | 3.13 ± 17.95 | 2.63 ± 20.61 |
| Change at FUV6; Emotional functioning | 2.27 ± 21.78 | 5.00 ± 17.28 |
| Change at FUV7; Emotional functioning | 5.77 ± 17.48 | -8.33 |
| Change at FUV8; Emotional functioning | 3.33 ± 28.01 | 0.00 |
| Change at FUV9; Emotional functioning | -16.67 ± 11.79 | — |
| Baseline; Cognitive functioning | 86.55 ± 16.78 | 89.86 ± 14.91 |
| Change at C1D1; Cognitive functioning | 0.0 ± 0.0 | -1.24 ± 14.01 |
| Change at C2D1; Cognitive functioning | -0.19 ± 15.34 | 0.25 ± 14.06 |
| Change at C3D1; Cognitive functioning | -0.32 ± 16.34 | -1.56 ± 17.50 |
| Change at C4D1; Cognitive functioning | -1.54 ± 17.41 | -0.26 ± 17.05 |
| Change at C5D1; Cognitive functioning | -1.94 ± 18.10 | -0.26 ± 14.28 |
| Change at C6D1; Cognitive functioning | -2.68 ± 16.97 | -0.77 ± 15.98 |
| Change at STC/EW; Cognitive functioning | -2.19 ± 17.65 | 1.04 ± 18.28 |
| Change at EoCTR; Cognitive functioning | -2.23 ± 18.11 | -0.27 ± 16.94 |
| Change at FUV1; Cognitive functioning | -2.02 ± 17.21 | -0.26 ± 15.98 |
| Change at FUV2; Cognitive functioning | 1.32 ± 16.16 | -2.38 ± 18.17 |
| Change at FUV3; Cognitive functioning | -1.63 ± 14.84 | -2.96 ± 18.24 |
| Change at FUV4; Cognitive functioning | 0.44 ± 17.63 | -1.77 ± 19.11 |
| Change at FUV5; Cognitive functioning | -1.49 ± 15.66 | -6.14 ± 21.67 |
| Change at FUV6; Cognitive functioning | -0.51 ± 14.72 | 0.00 ± 0.00 |
| Change at FUV7; Cognitive functioning | -1.28 ± 14.37 | 0.00 |
| Change at FUV8; Cognitive functioning | 0.00 ± 23.57 | 0.00 |
| Change at FUV9; Cognitive functioning | 16.67 ± 23.57 | — |
| Baseline; Social functioning | 82.48 ± 22.06 | 85.51 ± 21.18 |
| Change at C1D1; Social functioning | 0.0 ± 0.0 | -1.74 ± 19.92 |
| Change at C2D1; Social functioning | -2.44 ± 21.44 | 0.25 ± 18.46 |
| Change at C3D1; Social functioning | -2.32 ± 22.61 | 3.65 ± 25.45 |
| Change at C4D1; Social functioning | -0.55 ± 22.15 | 4.62 ± 20.09 |
| Change at C5D1; Social functioning | -5.48 ± 26.49 | 2.56 ± 20.46 |
| Change at C6D1; Social functioning | -5.13 ± 24.80 | 3.85 ± 24.61 |
| Change at STC/EW; Social functioning | -4.06 ± 27.71 | 1.04 ± 19.22 |
| Change at EoCTR; Social functioning | -0.47 ± 24.95 | 1.88 ± 20.49 |
| Change at FUV1; Social functioning | -1.08 ± 26.09 | 1.59 ± 24.27 |
| Change at FUV2; Social functioning | 0.58 ± 24.68 | 1.32 ± 27.97 |
| Change at FUV3; Social functioning | -0.91 ± 24.00 | 1.88 ± 25.98 |
| Change at FUV4; Social functioning | 1.97 ± 27.35 | 1.06 ± 32.12 |
| Change at FUV5; Social functioning | 1.79 ± 26.72 | 0.00 ± 33.79 |
| Change at FUV6; Social functioning | 1.52 ± 29.27 | 10.00 ± 14.91 |
| Change at FUV7; Social functioning | -2.56 ± 23.42 | 33.33 |
| Change at FUV8; Social functioning | -10.00 ± 22.36 | 33.33 |
| Change at FUV9; Social functioning | -25.00 ± 35.36 | — |
| Baseline; Global health status/QoL | 63.02 ± 21.45 | 67.39 ± 22.17 |
| Change at C1D1; Global health status/QoL | 0.0 ± 0.0 | 6.34 ± 18.41 |
| Change at C2D1; Global health status/QoL | 2.73 ± 21.69 | 5.35 ± 20.14 |
| Change at C3D1; Global health status/QoL | 2.34 ± 24.66 | 2.21 ± 23.58 |
| Change at C4D1; Global health status/QoL | 3.84 ± 22.26 | 7.05 ± 21.05 |
| Change at C5D1; Global health status/QoL | 7.36 ± 24.20 | 7.18 ± 21.94 |
| Change at C6D1; Global health status/QoL | 4.25 ± 25.00 | 5.90 ± 25.16 |
| Change at STC/EW; Global health status/QoL | 4.32 ± 26.20 | 6.51 ± 23.22 |
| Change at EoCTR; Global health status/QoL | 6.10 ± 23.65 | 7.66 ± 24.11 |
| Change at FUV1; Global health status/QoL | 5.91 ± 24.57 | 7.01 ± 25.01 |
| Change at FUV2; Global health status/QoL | 6.94 ± 24.81 | 4.50 ± 26.51 |
| Change at FUV3; Global health status/QoL | 4.80 ± 25.30 | 6.32 ± 27.36 |
| Change at FUV4; Global health status/QoL | 7.35 ± 26.77 | 6.38 ± 27.60 |
| Change at FUV5; Global health status/QoL | 4.46 ± 23.89 | 4.39 ± 18.08 |
| Change at FUV6; Global health status/QoL | 1.01 ± 24.00 | 5.00 ± 7.45 |
| Change at FUV7; Global health status/QoL | 8.33 ± 25.69 | 16.67 |
| Change at FUV8; Global health status/QoL | 6.67 ± 16.03 | 8.33 |
| Change at FUV9; Global health status/QoL | 0.00 ± 0.00 | — |
The EORTC QLQ-CLL16 module is designed for participants with Stage 0 to Stage 4 CLL. It is composed of 16 questions and there are four multi-item scales on Fatigue (2 items), Treatment-related side effects (TRSE, 4 items), Disease-related symptoms (DRS, 4 items), and Infection (4 items); and two single-item scales on social activities and future health worries. Multi-item scales score are reported and the total score for each multi-item scale was transformed to result in a total score range of 0 to 100, where higher score = poor HRQoL.
| units on a scale | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Baseline; TRSE | 14.29 ± 13.95 | 9.42 ± 8.80 |
| Change at C1D1; TRSE | 0.0 ± 0.0 | 0.12 ± 10.10 |
| Change at C2D1; TRSE | 1.62 ± 13.82 | 0.62 ± 12.76 |
| Change at C3D1; TRSE | -0.26 ± 13.76 | 1.98 ± 14.72 |
| Change at C4D1; TRSE | -0.49 ± 13.97 | 0.52 ± 11.87 |
| Change at C5D1; TRSE | -0.51 ± 14.57 | 0.64 ± 10.02 |
| Change at C6D1; TRSE | 0.46 ± 15.51 | -0.13 ± 10.04 |
| Change at STC/EW; TRSE | 0.81 ± 18.11 | 0.13 ± 10.76 |
| Change at EoCTR; TRSE | -0.88 ± 16.06 | 0.26 ± 12.61 |
| Change at FUV1; TRSE | -1.20 ± 14.87 | 1.19 ± 12.24 |
| Change at FUV2; TRSE | -1.70 ± 15.28 | 2.65 ± 14.03 |
| Change at FUV3; TRSE | -2.08 ± 12.64 | -0.13 ± 13.70 |
| Change at FUV4; TRSE | -1.97 ± 12.76 | 2.84 ± 15.18 |
| Change at FUV5; TRSE | -2.68 ± 11.02 | 1.32 ± 10.49 |
| Change at FUV6; TRSE | -1.01 ± 12.10 | -1.67 ± 3.73 |
| Change at FUV7; TRSE | 2.56 ± 22.67 | -8.33 |
| Change at FUV8; TRSE | 1.67 ± 13.69 | 0.00 |
| Change at FUV9; TRSE | 8.33 ± 11.79 | — |
| Baseline; DRS | 19.57 ± 16.81 | 16.95 ± 17.37 |
| Change at C1D1; DRS | 0.0 ± 0.0 | -2.74 ± 16.18 |
| Change at C2D1; DRS | -3.33 ± 16.05 | -4.77 ± 16.84 |
| Change at C3D1; DRS | -4.77 ± 16.49 | -3.35 ± 17.48 |
| Change at C4D1; DRS | -6.03 ± 16.51 | -5.12 ± 17.72 |
| Change at C5D1; DRS | -5.90 ± 16.73 | -4.79 ± 17.50 |
| Change at C6D1; DRS | -6.40 ± 17.26 | -5.30 ± 16.72 |
| Change at STC/EW; DRS | -5.80 ± 18.52 | -6.51 ± 18.45 |
| Change at EoCTR; DRS | -6.57 ± 17.21 | -5.86 ± 20.38 |
| Change at FUV1; DRS | -6.55 ± 15.73 | -5.82 ± 19.20 |
| Change at FUV2; DRS | -8.63 ± 14.39 | -3.57 ± 18.31 |
| Change at FUV3; DRS | -7.37 ± 14.88 | -3.76 ± 19.25 |
| Change at FUV4; DRS | -8.55 ± 18.56 | -2.66 ± 20.49 |
| Change at FUV5; DRS | -8.33 ± 16.13 | -2.19 ± 19.41 |
| Change at FUV6; DRS | -6.31 ± 16.01 | -3.33 ± 13.94 |
| Change at FUV7; DRS | -15.38 ± 20.08 | -8.33 |
| Change at FUV8; DRS | -10.00 ± 16.03 | -8.33 |
| Change at FUV9; DRS | -4.17 ± 5.89 | — |
| Baseline; Fatigue | 28.76 ± 24.66 | 21.74 ± 20.67 |
| Change at C1D1; Fatigue | 0.0 ± 0.0 | -2.24 ± 20.29 |
| Change at C2D1; Fatigue | -2.55 ± 22.86 | -5.47 ± 21.40 |
| Change at C3D1; Fatigue | -2.83 ± 25.17 | -3.17 ± 23.73 |
| Change at C4D1; Fatigue | -3.18 ± 23.23 | -4.17 ± 22.02 |
| Change at C5D1; Fatigue | -2.38 ± 27.52 | -4.36 ± 20.89 |
| Change at C6D1; Fatigue | -2.66 ± 26.35 | -2.31 ± 21.42 |
| Change at STC/EW; Fatigue | -3.11 ± 28.64 | -4.69 ± 21.30 |
| Change at EoCTR; Fatigue | -6.69 ± 26.78 | -3.97 ± 24.27 |
| Change at FUV1; Fatigue | -6.37 ± 26.61 | -4.23 ± 22.99 |
| Change at FUV2; Fatigue | -6.64 ± 24.55 | -1.85 ± 24.70 |
| Change at FUV3; Fatigue | -5.79 ± 23.29 | -2.42 ± 23.73 |
| Change at FUV4; Fatigue | -9.65 ± 26.84 | -0.35 ± 25.18 |
| Change at FUV5; Fatigue | -6.55 ± 25.56 | 3.51 ± 23.95 |
| Change at FUV6; Fatigue | -5.05 ± 24.82 | 3.33 ± 24.72 |
| Change at FUV7; Fatigue | -10.26 ± 30.08 | -33.33 |
| Change at FUV8; Fatigue | -6.67 ± 19.00 | 0.00 |
| Change at FUV9; Fatigue | -8.33 ± 11.79 | — |
| Baseline; Infection | 15.92 ± 17.63 | 14.01 ± 18.99 |
| Change at C1D1; Infection | 0.0 ± 0.0 | -2.24 ± 20.03 |
| Change at C2D1; Infection | -0.02 ± 19.98 | -3.61 ± 21.72 |
| Change at C3D1; Infection | -1.66 ± 19.21 | -1.32 ± 20.48 |
| Change at C4D1; Infection | -1.44 ± 22.07 | -3.13 ± 21.28 |
| Change at C5D1; Infection | -1.91 ± 24.00 | -2.56 ± 23.47 |
| Change at C6D1; Infection | -1.09 ± 20.66 | -2.95 ± 20.54 |
| Change at STC/EW; Infection | -0.12 ± 23.28 | -1.69 ± 23.34 |
| Change at EoCTR; Infection | -0.55 ± 21.73 | -3.44 ± 25.78 |
| Change at FUV1; Infection | 1.08 ± 18.77 | -2.65 ± 26.51 |
| Change at FUV2; Infection | 0.05 ± 23.29 | -0.53 ± 25.74 |
| Change at FUV3; Infection | -1.90 ± 16.97 | -0.54 ± 26.48 |
| Change at FUV4; Infection | -4.24 ± 16.71 | 0.53 ± 25.56 |
| Change at FUV5; Infection | -4.51 ± 22.66 | 7.46 ± 27.20 |
| Change at FUV6; Infection | -1.60 ± 18.90 | 8.33 ± 15.59 |
| Change at FUV7; Infection | -0.43 ± 21.84 | -16.67 |
| Change at FUV8; Infection | 8.89 ± 23.36 | -25.00 |
| Change at FUV9; Infection | -2.78 ± 3.93 | — |
An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A Serious Adverse Event (SAE) is any significant hazard, contraindication, side effect that is fatal or life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above. AEs were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE, v4.0)
| Participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| Adverse Events | 185 | 194 |
| Serious Adverse Events | 84 | 101 |
An AE was defined as any untoward medical occurrence in a participant administered with Mircera and which does not necessarily have a causal relationship with Mircera. A SAE is any significant hazard, contraindication, side effect that is fatal or life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is medically significant or requires intervention to prevent one or other of the outcomes listed above. TLS and IRRs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe or medically significant; Grade 4 = Life-threatening; Grade 5 = Death. A higher grade indicates a worse outcome.
| Participants | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study |
|---|---|---|
| TLS | 2 | 6 |
| IRRs | 10 | 4 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over From signing of informed consent form up to approximately 8 years 5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bendamustine + Rituximab Main Study | 84/188 (44.7%) | 84/188 (44.7%) | 177/188 (94.1%) |
| Venetoclax + Rituximab Main Study | 60/194 (30.9%) | 101/194 (52.1%) | 190/194 (97.9%) |
| Bendamustine + Rituximab Crossover Substudy | 1/9 (11.1%) | 5/9 (55.6%) | 5/9 (55.6%) |
| Venetoclax + Rituximab Re-Treatment Substudy | 8/25 (32%) | 13/25 (52%) | 9/25 (36%) |
| Event | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study | Bendamustine + Rituximab Crossover Substudy | Venetoclax + Rituximab Re-Treatment Substudy |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 15/188 | 19/194 | 1/9 | 3/25 |
| NeutropeniaBlood and lymphatic system disorders | 3/188 | 3/194 | 1/9 | 0/25 |
| Abdominal painGastrointestinal disorders | 0/188 | 1/194 | 1/9 | 1/25 |
| Rhinovirus infectionInfections and infestations | 0/188 | 1/194 | 1/9 | 0/25 |
| SepsisInfections and infestations | 4/188 | 1/194 | 1/9 | 0/25 |
| COVID-19Infections and infestations | 0/188 | 1/194 | 1/9 | 1/25 |
| GastroenteritisInfections and infestations | 0/188 | 0/194 | 1/9 | 0/25 |
| Pneumonia pseudomonalInfections and infestations | 0/188 | 0/194 | 1/9 | 0/25 |
| Electrocardiogram QT prolongedInvestigations | 0/188 | 0/194 | 1/9 | 0/25 |
| SARS-CoV-2 test positiveInvestigations | 0/188 | 0/194 | 1/9 | 0/25 |
| Event | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study | Bendamustine + Rituximab Crossover Substudy | Venetoclax + Rituximab Re-Treatment Substudy |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 84/188 | 120/194 | 3/9 | 5/25 |
| DiarrhoeaGastrointestinal disorders | 31/188 | 78/194 | 0/9 | 3/25 |
| NauseaGastrointestinal disorders | 64/188 | 42/194 | 0/9 | 0/25 |
| Upper respiratory tract infectionInfections and infestations | 28/188 | 45/194 | 0/9 | 1/25 |
| ThrombocytopeniaBlood and lymphatic system disorders | 42/188 | 23/194 | 0/9 | 2/25 |
| AnaemiaBlood and lymphatic system disorders | 40/188 | 28/194 | 1/9 | 1/25 |
| Infusion related reactionInjury, poisoning and procedural complications | 40/188 | 16/194 | 0/9 | 0/25 |
| ConstipationGastrointestinal disorders | 39/188 | 27/194 | 0/9 | 0/25 |
| FatigueGeneral disorders | 39/188 | 35/194 | 0/9 | 1/25 |
| CoughRespiratory, thoracic and mediastinal disorders | 31/188 | 36/194 | 0/9 | 0/25 |
Intent-to-treat (ITT) population included all randomized participants, with participants grouped according to randomized treatment group, regardless of the actual treatment received.
| Age, Continuous(years) | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study | Total |
|---|---|---|---|
| Mean | 64.4 ± 9.6 | 63.9 ± 10.5 | 64.1 ± 10.1 |
| Sex: Female, Male(Participants) | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study | Total |
|---|---|---|---|
| Female | 44 | 58 | 102 |
| Male | 151 | 136 | 287 |
| Ethnicity (NIH/OMB)(Participants) | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 |
| Not Hispanic or Latino | 186 | 186 | 372 |
| Unknown or Not Reported | 6 | 4 | 10 |
| Race (NIH/OMB)(Participants) | Bendamustine + Rituximab Main Study | Venetoclax + Rituximab Main Study | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 6 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 178 | 181 | 359 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 11 | 7 | 18 |
Showing the first 100 of 111 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Mar 2014 to primary completion in May 2017, 37 months.
Results were first posted in Oct 2018, 1 year 4 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 37 months is below that.
Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax
Leukemia, Lymphocytic, Chronic, B-Cell →